NCT03925870View on ClinicalTrials.gov

KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 21, 2019

Primary Completion Date

August 26, 2021

Study Completion Date

July 4, 2022

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

KN046

Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first

Trial Locations (1)

Unknown

307 Hospital of PLA, Beijing

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

NCT03925870 - KN046 in Subjects With Late Stage Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter